Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.95
Change (%) Stock is Down 0.02 (1.02%)
Volume156,578
Data as of 07/21/17 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote

Bloomberg Baystate Business Hour -- The Bloomberg Baystate Business Hour: Knees and Beer – Tom Moroney and Anne Mostue – 11 July 2017

(The Histogenics portion of the program begins 13 minutes into the show and ends at 18:45.)

Recent NewsMore >>
DateTitle 
07/11/17Histogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study
– Findings Augment Growing Body of Information to Support the Manufacture of Current and Next-Generation NeoCart® Implants –  – 3-D Bioprinting May Enable More Efficient Production of Next Generation NeoCart Implants – WALTHAM, Mass., July 11, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the online publication in the Journal Biofabr... 
Printer Friendly Version
06/27/17Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
– On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 – Articular cartilage can be damaged by injury or normal wear and tear (http://www.neocartimplant.com/cartilage-injury). – Novel Tissue Implant Potentially Ac... 
Printer Friendly Version
06/05/17Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer
‒ Experienced Biotechnology Business Development & Strategic Planning Executive to Lead Commercial Partnership Activities ‒ WALTHAM, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the appointment of Donald Haut, Ph.D. as its Chief Business Officer.  Dr. Haut brings more than 20 years of executive management experience in ... 
Printer Friendly Version
05/16/17Histogenics Corporation to Present at Upcoming Industry Conferences
WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Management will be presenting at several upcoming industry conferences.  12th World Advanced Therapies & Regenerative Medicine Congress – London, England (May 17-19, 2017) Adam Gridley, Histogenics’ CEO, will be participating in several panels disc... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.